Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 18/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931538 | 0.91 | PTGES (1.00) | PTGESKCNH2FFAR2 | |
| SCHEMBL9931878 | 0.85 | PTGES (1.00) | PTGESKCNH2 | |
| SCHEMBL9931451 | 0.78 | PTGES (1.00) | PTGESFFAR2 | |
| SCHEMBL9931721 | 0.73 | PTGES (1.00) | PTGES | |
| SCHEMBL9931777 | 0.71 | PTGES (1.00) | PTGES | |
| SCHEMBL9931961 | 0.71 | PTGES (0.68) | PTGESLMNA | |
| Ly-3031207 SCHEMBL9931208 | 0.70 | PTGES (1.00) | PTGES | |
| SCHEMBL9932326 | 0.70 | PTGES (1.00) | PTGES | |
| SCHEMBL9931813 | 0.70 | PTGES (1.00) | PTGES | |
| SCHEMBL9960827 | 0.69 | PTGES (0.73) | PTGESFFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252831-B2 | Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252831-B2 | Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2012087771-A1 | NOVEL IMIDAZOLE-2-BENZAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF OSTEOARTHRITIS | ELI LILLY AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ARG2, HDAC6, COL2A1 | PTGES 550/4885KCNH2 1643/4885FFAR2 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.